Second Line Treatment of Non-Small Cell Lung Cancer: Clinical; Pathological and Molecular Aspects of Novel Promising Drugs

Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therap...

Ausführliche Beschreibung

Bibliographische Detailangaben

Hauptverfasser:	Umberto Malapelle, Pierlorenzo Pallante
Format:	Online
Sprache:	Englisch
Veröffentlicht:	Frontiers Media SA 2021
Schlagworte:	R5-920 Alectinib Liquid Biopsy Non-Small Cell Lung Cancer Afatinib Nivolumab Immunotherapy Nintedanib Dacomitinib Second-Line Treatment Tyrosine Kinase Inhibitor thema EDItEUR::M Medicine and Nursing
Online-Zugang:	25575
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!